BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35213212)

  • 1. Impact of the Oncology Care Model on Use of Supportive Care Medications During Cancer Treatment.
    Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
    J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
    Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
    JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    Keating NL; Brooks GA; Landrum MB; Liu PH; Wolf R; Riedel LE; Kapadia NS; Jhatakia S; Tripp A; Simon C; Hsu VD; Kummet CM; Hassol A
    J Natl Cancer Inst; 2022 Jun; 114(6):871-877. PubMed ID: 35134972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy.
    Kapadia NS; Brooks GA; Landrum MB; Riedel L; Liu PH; Hassol A; Tripp AS; Jhatakia S; Kummet CM; Keating NL
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):39-46. PubMed ID: 35150787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practice patterns among oncologists participating in the oncology care model after three years.
    Walker B; Wilfong L; Frytak J; Robert N
    J Cancer Policy; 2021 Sep; 29():100294. PubMed ID: 35559949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
    Walker B; Frytak J; Hayes J; Neubauer M; Robert N; Wilfong L
    JAMA Netw Open; 2020 May; 3(5):e205165. PubMed ID: 32421185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model.
    Wirtz HS; Hepp Z; Grewal S; Wright P; Fuldeore R; Tomicki S; Hirsch J; Dieguez G; Blakely LJ
    Am J Manag Care; 2023 May; 29(5):e136-e142. PubMed ID: 37229787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling Episode-Based Payments for Cancer Using Commercial Claims Data.
    Polson M; Lord T; Evangelatos T; Kangethe A; Speicher LC; Barrientos S; Zacker C
    J Manag Care Spec Pharm; 2019 Feb; 25(2):235-245. PubMed ID: 30698092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
    Stephens JM; Bensink M; Bowers C; Hollenbeak CS
    Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.
    Manz CR; Tramontano AC; Uno H; Parikh RB; Bekelman JE; Schrag D
    JAMA Netw Open; 2022 Sep; 5(9):e2234161. PubMed ID: 36173630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
    McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
    Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model.
    Baumgardner JR; Shahabi A; Linthicum MT; Zacker C; Lakdawalla DN
    J Oncol Pract; 2018 Nov; 14(11):e699-e710. PubMed ID: 30423271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
    Yang J; Chaudhry BI; Yue AT; Roth JA; Kelton JM; Shelbaya A; Tran L; Li M
    Adv Ther; 2024 Jan; 41(1):349-363. PubMed ID: 37957523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice radiation patterns among oncologists in the Oncology Care Model.
    Walker B; Kavadi V; Wilfong L; Robert N
    Am J Manag Care; 2022 Oct; 28(10):515-519. PubMed ID: 36252170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Findings From the Oncology Care Model Evaluation.
    Brooks GA; Jhatakia S; Tripp A; Landrum MB; Christian TJ; Newes-Adeyi G; Cafardi S; Hassol A; Simon C; Keating NL
    J Oncol Pract; 2019 Oct; 15(10):e888-e896. PubMed ID: 31393807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpreting Oncology Care Model Data to Drive Value-Based Care: A Prostate Cancer Analysis.
    Ennis RD; Parikh AB; Sanderson M; Liu M; Isola L
    J Oncol Pract; 2019 Mar; 15(3):e238-e246. PubMed ID: 30742551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Addition of Clinical and Staging Data to Improve the Pricing Methodology of the Oncology Care Model.
    Dreyer TRF; Hamilton E; Dahl A; Desai B; Kircher S; Polite B; Schroeder C; Fukui M; Hayes-Lattin B; Horvath KA
    JCO Oncol Pract; 2022 Nov; 18(11):e1899-e1907. PubMed ID: 36252153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.
    Castellanos EH; Orlando A; Ma X; Parikh RB; O'Connell G; Meropol NJ; Hamrick J; Adamson BJS
    JCO Oncol Pract; 2020 Oct; 16(10):e1216-e1221. PubMed ID: 32496874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
    Li S; Liu J; Guo H; Gawade PL; Kim C; Bensink ME; Chandler D
    Support Care Cancer; 2020 Jun; 28(6):2637-2649. PubMed ID: 31624920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.